1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

ADC Specialist LegoChem Takes Orion’s Hand As Long-Term Partner

26% Stake Should Ensure Competitive R&D

 
• By Jung Won Shin

Korean confectionery group Orion has become the biggest shareholder in compatriot ADC specialist LegoChem Biosciences, in a decisive step to move into the biotech sector as a new growth engine. For LegoChem, the alliance provides a friendly strategic partner and should enable a boost in R&D spending as it seeks to aggressively progress clinical trials and become a global player.

partnership
LegoChem’s Alliance With Orion In Line With Vision 2030 Ambitions • Source: Shutterstock

LegoChem Biosciences, Inc., a leading South Korean antibody-drug conjugate (ADC) platform company in the news recently for a major alliance, has generated more headlines through a surprise shareholding tie-up with a major domestic confectionery group, through which it will raise KRW548.5bn ($413m).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By Jung Won Shin

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.

Korea Needs To Think Bigger On M&As: KHIDI

 
• By Jung Won Shin and Kosh Naran

A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.

More from Focus On Asia

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

 
• By Dexter Jie Yan

AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.